PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31901211-0	2020	The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases.	diminazene aceturate	75-95	angiotensin converting enzyme 2	Homo sapiens	59-63
31901211-0	2020	The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases.	diminazene aceturate	97-101	angiotensin converting enzyme 2	Homo sapiens	59-63
31901211-10	2020	The antitrypanosomal agent, diminazene aceturate (DIZE), is one approach in activating ACE2.	diminazene aceturate	28-48	angiotensin converting enzyme 2	Homo sapiens	87-91
31901211-10	2020	The antitrypanosomal agent, diminazene aceturate (DIZE), is one approach in activating ACE2.	diminazene aceturate	50-54	angiotensin converting enzyme 2	Homo sapiens	87-91
31987711-3	2020	Here, we examined whether the ACE2 activator diminazene aceturate (DIZE) can prevent the formalin-induced nociception in mice.	diminazene aceturate	45-65	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	30-34
32368013-11	2020	Conclusion: The overexpression of ACE2 and treatment with DIZE can ameliorate EMT in silicotic mice via activation of the ACE2-Ang-(1-7)-Mas receptor axis, and these changes are accompanied by suppression of the ACE-Ang II-AT1 receptor axis.	diminazene aceturate	58-62	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	122-126
32368013-11	2020	Conclusion: The overexpression of ACE2 and treatment with DIZE can ameliorate EMT in silicotic mice via activation of the ACE2-Ang-(1-7)-Mas receptor axis, and these changes are accompanied by suppression of the ACE-Ang II-AT1 receptor axis.	diminazene aceturate	58-62	angiogenin, ribonuclease A family, member 6	Mus musculus	127-135
31987711-3	2020	Here, we examined whether the ACE2 activator diminazene aceturate (DIZE) can prevent the formalin-induced nociception in mice.	diminazene aceturate	67-71	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	30-34
31982938-5	2020	We now show that enhancement of brain ACE2 activity, a major effector of rRAS, by intraperitoneal administration of diminazene aceturate (DIZE), an established activator of ACE2, lowered hippocampal Abeta and restored cognition in mid-aged (13-14-month-old) symptomatic Tg2576 mice.	diminazene aceturate	116-136	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	38-42
31982938-5	2020	We now show that enhancement of brain ACE2 activity, a major effector of rRAS, by intraperitoneal administration of diminazene aceturate (DIZE), an established activator of ACE2, lowered hippocampal Abeta and restored cognition in mid-aged (13-14-month-old) symptomatic Tg2576 mice.	diminazene aceturate	116-136	RAS related	Rattus norvegicus	73-77
31982938-5	2020	We now show that enhancement of brain ACE2 activity, a major effector of rRAS, by intraperitoneal administration of diminazene aceturate (DIZE), an established activator of ACE2, lowered hippocampal Abeta and restored cognition in mid-aged (13-14-month-old) symptomatic Tg2576 mice.	diminazene aceturate	116-136	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	173-177
31982938-5	2020	We now show that enhancement of brain ACE2 activity, a major effector of rRAS, by intraperitoneal administration of diminazene aceturate (DIZE), an established activator of ACE2, lowered hippocampal Abeta and restored cognition in mid-aged (13-14-month-old) symptomatic Tg2576 mice.	diminazene aceturate	116-136	amyloid beta (A4) precursor protein	Mus musculus	199-204
31982938-5	2020	We now show that enhancement of brain ACE2 activity, a major effector of rRAS, by intraperitoneal administration of diminazene aceturate (DIZE), an established activator of ACE2, lowered hippocampal Abeta and restored cognition in mid-aged (13-14-month-old) symptomatic Tg2576 mice.	diminazene aceturate	138-142	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	38-42
31982938-5	2020	We now show that enhancement of brain ACE2 activity, a major effector of rRAS, by intraperitoneal administration of diminazene aceturate (DIZE), an established activator of ACE2, lowered hippocampal Abeta and restored cognition in mid-aged (13-14-month-old) symptomatic Tg2576 mice.	diminazene aceturate	138-142	RAS related	Rattus norvegicus	73-77
31982938-5	2020	We now show that enhancement of brain ACE2 activity, a major effector of rRAS, by intraperitoneal administration of diminazene aceturate (DIZE), an established activator of ACE2, lowered hippocampal Abeta and restored cognition in mid-aged (13-14-month-old) symptomatic Tg2576 mice.	diminazene aceturate	138-142	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	173-177
31982938-5	2020	We now show that enhancement of brain ACE2 activity, a major effector of rRAS, by intraperitoneal administration of diminazene aceturate (DIZE), an established activator of ACE2, lowered hippocampal Abeta and restored cognition in mid-aged (13-14-month-old) symptomatic Tg2576 mice.	diminazene aceturate	138-142	amyloid beta (A4) precursor protein	Mus musculus	199-204
31643111-1	2020	Diminazene aceturate (DIZE) is an anti-protozoan compound that has been previously reported to increase the activity of the angiotensin-converting enzyme 2 (ACE2) and thus increase Angiotensin-(1-7) production, leading to cardioprotection against post-myocardial infarction dysfunction and structural remodelling.	diminazene aceturate	0-20	angiotensin converting enzyme 2	Homo sapiens	124-155
31643111-1	2020	Diminazene aceturate (DIZE) is an anti-protozoan compound that has been previously reported to increase the activity of the angiotensin-converting enzyme 2 (ACE2) and thus increase Angiotensin-(1-7) production, leading to cardioprotection against post-myocardial infarction dysfunction and structural remodelling.	diminazene aceturate	0-20	angiotensin converting enzyme 2	Homo sapiens	157-161
31643111-1	2020	Diminazene aceturate (DIZE) is an anti-protozoan compound that has been previously reported to increase the activity of the angiotensin-converting enzyme 2 (ACE2) and thus increase Angiotensin-(1-7) production, leading to cardioprotection against post-myocardial infarction dysfunction and structural remodelling.	diminazene aceturate	22-26	angiotensin converting enzyme 2	Homo sapiens	124-155
31643111-1	2020	Diminazene aceturate (DIZE) is an anti-protozoan compound that has been previously reported to increase the activity of the angiotensin-converting enzyme 2 (ACE2) and thus increase Angiotensin-(1-7) production, leading to cardioprotection against post-myocardial infarction dysfunction and structural remodelling.	diminazene aceturate	22-26	angiotensin converting enzyme 2	Homo sapiens	157-161
31506648-1	2019	The aim of this study was to investigate whether treatment with diminazene aceturate (DIZE), a putative ACE2 activator, or with angiotensin-(1-7) during pregnancy could attenuate the development of cardiovascular dysfunction in the adult offspring of spontaneously hypertensive rats (SHRs).	diminazene aceturate	64-84	angiotensin I converting enzyme 2	Rattus norvegicus	104-108
30006298-0	2018	ACE2 activator diminazene aceturate reduces adiposity but preserves lean mass in young and old rats.	diminazene aceturate	15-35	angiotensin I converting enzyme 2	Rattus norvegicus	0-4
30092400-0	2018	The ACE 2 activator diminazene aceturate (DIZE) improves left ventricular diastolic dysfunction following myocardial infarction in rats.	diminazene aceturate	20-40	angiotensin I converting enzyme 2	Rattus norvegicus	4-9
30092400-0	2018	The ACE 2 activator diminazene aceturate (DIZE) improves left ventricular diastolic dysfunction following myocardial infarction in rats.	diminazene aceturate	42-46	angiotensin I converting enzyme 2	Rattus norvegicus	4-9
30092400-1	2018	Diminazene aceturate (DIZE) has been reported to enhance the catalytic efficiency of ACE-2 and presumably increases angiotensin 1-7 generation, interfering with cardiac remodeling after myocardial infarction (MI).	diminazene aceturate	0-20	angiotensin I converting enzyme 2	Rattus norvegicus	85-90
30092400-1	2018	Diminazene aceturate (DIZE) has been reported to enhance the catalytic efficiency of ACE-2 and presumably increases angiotensin 1-7 generation, interfering with cardiac remodeling after myocardial infarction (MI).	diminazene aceturate	22-26	angiotensin I converting enzyme 2	Rattus norvegicus	85-90
31393582-2	2019	METHODS: Adult mice were exposed to 95% O2 for 72 h to induce hyperoxic lung injury, and simultaneously treated with ACE2 agonist diminazene aceturate (DIZE) or inhibitor MLN-4760.	diminazene aceturate	130-150	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	117-121
31393582-2	2019	METHODS: Adult mice were exposed to 95% O2 for 72 h to induce hyperoxic lung injury, and simultaneously treated with ACE2 agonist diminazene aceturate (DIZE) or inhibitor MLN-4760.	diminazene aceturate	152-156	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	117-121
30840489-0	2019	Is the cardioprotective effect of the ACE2 activator diminazene aceturate more potent than the ACE inhibitor enalapril on acute myocardial infarction in rats?	diminazene aceturate	53-73	angiotensin I converting enzyme 2	Rattus norvegicus	38-42
30840489-0	2019	Is the cardioprotective effect of the ACE2 activator diminazene aceturate more potent than the ACE inhibitor enalapril on acute myocardial infarction in rats?	diminazene aceturate	53-73	angiotensin I converting enzyme	Rattus norvegicus	38-41
30383059-4	2018	Furthermore, studying the ground-state pathways shows that a fraction of the molecules relaxes back to the E-azo,s-trans isomer while the other part photoisomerizes to the Z-azo,s-trans via a hula-twist motion, as evidenced by experimental quantum yields of Phi   0.5 found for berenil in water, ethylene glycol, or bound to beta-trypsin.	diminazene aceturate	278-285	serine protease 1	Homo sapiens	325-337
29729200-10	2018	Similarly, while pharmacological induction of SAT1 and SMOX using the polyamine analogue bis(ethyl)norspermine (BENSPM) alleviated asthmatic features with reduced TSLP levels and BEC apoptosis, pharmacological inhibition of these enzymes using BERENIL or MDL72527, respectively, worsened them.	diminazene aceturate	244-251	spermidine/spermine N1-acetyl transferase 1	Mus musculus	46-50
29729200-10	2018	Similarly, while pharmacological induction of SAT1 and SMOX using the polyamine analogue bis(ethyl)norspermine (BENSPM) alleviated asthmatic features with reduced TSLP levels and BEC apoptosis, pharmacological inhibition of these enzymes using BERENIL or MDL72527, respectively, worsened them.	diminazene aceturate	244-251	spermine oxidase	Mus musculus	55-59
30006298-3	2018	It was hypothesized that activation of ACE2 via diminazene aceturate (DIZE) will significantly reduce body weight of rats fed a high fat diet.	diminazene aceturate	48-68	angiotensin I converting enzyme 2	Rattus norvegicus	39-43
30006298-3	2018	It was hypothesized that activation of ACE2 via diminazene aceturate (DIZE) will significantly reduce body weight of rats fed a high fat diet.	diminazene aceturate	70-74	angiotensin I converting enzyme 2	Rattus norvegicus	39-43
29691582-1	2018	This study was aimed to explore the effect of angiotensin converting enzyme 2 (ACE2) agonist diminazene aceturate (DIZE) on acute lung injury (ALI) induced by limb ischemia-reperfusion (LIR) in mice.	diminazene aceturate	93-113	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	46-77
29977014-3	2018	Diminazene aceturate (DIZE), a small molecule drug approved by the US Food and Drug Administration, which is used to treat human trypanosomiasis, has been shown to have antifibrotic properties by enhancing ACE2 activity.	diminazene aceturate	0-20	angiotensin converting enzyme 2	Homo sapiens	206-210
29977014-3	2018	Diminazene aceturate (DIZE), a small molecule drug approved by the US Food and Drug Administration, which is used to treat human trypanosomiasis, has been shown to have antifibrotic properties by enhancing ACE2 activity.	diminazene aceturate	22-26	angiotensin converting enzyme 2	Homo sapiens	206-210
29977014-7	2018	Moreover, DIZE-inhibited NOX enzyme assembly and ROS generation, activation of profibrotic transcription factors including p38, Erk1/2 and Smad2/3 proteins and proinflammatory and profibrotic cytokine release.	diminazene aceturate	10-14	mitogen-activated protein kinase 14	Mus musculus	123-126
29977014-7	2018	Moreover, DIZE-inhibited NOX enzyme assembly and ROS generation, activation of profibrotic transcription factors including p38, Erk1/2 and Smad2/3 proteins and proinflammatory and profibrotic cytokine release.	diminazene aceturate	10-14	mitogen-activated protein kinase 3	Mus musculus	128-134
29977014-7	2018	Moreover, DIZE-inhibited NOX enzyme assembly and ROS generation, activation of profibrotic transcription factors including p38, Erk1/2 and Smad2/3 proteins and proinflammatory and profibrotic cytokine release.	diminazene aceturate	10-14	SMAD family member 2	Mus musculus	139-146
29288933-7	2018	More recent studies favor the development of targeting the downstream ACE2/Ang (1-7)/Mas receptor pathway, in which diminazene aceturate, an ACE2 activator, GSK2586881, a recombinant ACE2, and AV0991, a Mas receptor agonist, showed much potential for further development.	diminazene aceturate	116-136	angiotensin converting enzyme 2	Homo sapiens	70-74
29691582-1	2018	This study was aimed to explore the effect of angiotensin converting enzyme 2 (ACE2) agonist diminazene aceturate (DIZE) on acute lung injury (ALI) induced by limb ischemia-reperfusion (LIR) in mice.	diminazene aceturate	93-113	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	79-83
29691582-1	2018	This study was aimed to explore the effect of angiotensin converting enzyme 2 (ACE2) agonist diminazene aceturate (DIZE) on acute lung injury (ALI) induced by limb ischemia-reperfusion (LIR) in mice.	diminazene aceturate	115-119	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	46-77
29691582-1	2018	This study was aimed to explore the effect of angiotensin converting enzyme 2 (ACE2) agonist diminazene aceturate (DIZE) on acute lung injury (ALI) induced by limb ischemia-reperfusion (LIR) in mice.	diminazene aceturate	115-119	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	79-83
27571511-3	2016	We hypothesised that diminazene aceturate (DIZE), which has been described as having an off-target effect to activate ACE2, would have beneficial cardiac effects in STNx rats.	diminazene aceturate	21-41	angiotensin I converting enzyme 2	Rattus norvegicus	118-122
27592222-5	2016	As the activator of ACE2, diminazene aceturate (DIZE) inhibited increase of blood pressure, collagen deposition, and KCa3.1 protein expression in myocardium of WT mice induced by Ang II.	diminazene aceturate	26-46	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	20-24
27592222-5	2016	As the activator of ACE2, diminazene aceturate (DIZE) inhibited increase of blood pressure, collagen deposition, and KCa3.1 protein expression in myocardium of WT mice induced by Ang II.	diminazene aceturate	26-46	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	Mus musculus	117-123
27592222-5	2016	As the activator of ACE2, diminazene aceturate (DIZE) inhibited increase of blood pressure, collagen deposition, and KCa3.1 protein expression in myocardium of WT mice induced by Ang II.	diminazene aceturate	26-46	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	179-185
27592222-5	2016	As the activator of ACE2, diminazene aceturate (DIZE) inhibited increase of blood pressure, collagen deposition, and KCa3.1 protein expression in myocardium of WT mice induced by Ang II.	diminazene aceturate	48-52	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	20-24
27592222-5	2016	As the activator of ACE2, diminazene aceturate (DIZE) inhibited increase of blood pressure, collagen deposition, and KCa3.1 protein expression in myocardium of WT mice induced by Ang II.	diminazene aceturate	48-52	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	Mus musculus	117-123
27592222-5	2016	As the activator of ACE2, diminazene aceturate (DIZE) inhibited increase of blood pressure, collagen deposition, and KCa3.1 protein expression in myocardium of WT mice induced by Ang II.	diminazene aceturate	48-52	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	179-185
27367913-3	2016	This review focuses on experimental studies that have used the off-target effects of the antitrypanosomal agent, diminazene aceturate (DIZE) to activate ACE2.	diminazene aceturate	113-133	angiotensin converting enzyme 2	Homo sapiens	153-157
27367913-3	2016	This review focuses on experimental studies that have used the off-target effects of the antitrypanosomal agent, diminazene aceturate (DIZE) to activate ACE2.	diminazene aceturate	135-139	angiotensin converting enzyme 2	Homo sapiens	153-157
29434943-0	2018	Mechanism of anticancer action of novel berenil complex of platinum(II) combined with anti-MUC1 in MCF-7 breast cancer cells.	diminazene aceturate	40-47	mucin 1, cell surface associated	Homo sapiens	91-95
28688122-0	2017	Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type1 diabetes.	diminazene aceturate	0-20	angiotensin I converting enzyme 2	Rattus norvegicus	67-71
28688122-0	2017	Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type1 diabetes.	diminazene aceturate	0-20	angiotensin II receptor, type 2	Rattus norvegicus	76-79
28688122-4	2017	Here we have tested the effects of the ACE2 activator, diminazene aceturate (DIZE), in a model of DN.	diminazene aceturate	55-75	angiotensin I converting enzyme 2	Rattus norvegicus	39-43
28688122-4	2017	Here we have tested the effects of the ACE2 activator, diminazene aceturate (DIZE), in a model of DN.	diminazene aceturate	77-81	angiotensin I converting enzyme 2	Rattus norvegicus	39-43
28764253-11	2017	Berenil at a concentration of 150 microg/ml showed the highest expression of FRA16B.	diminazene aceturate	0-7	fragile site, distamycin A type, rare, fra(16)(q22.1)	Homo sapiens	77-83
27571511-3	2016	We hypothesised that diminazene aceturate (DIZE), which has been described as having an off-target effect to activate ACE2, would have beneficial cardiac effects in STNx rats.	diminazene aceturate	43-47	angiotensin I converting enzyme 2	Rattus norvegicus	118-122
27533767-1	2016	The present study sought to determine cardiovascular effects of aerobic training associated with diminazene aceturate (DIZE), an activator of the angiotensin converting enzyme 2, in spontaneously hypertensive rats (SHRs).	diminazene aceturate	97-117	angiotensin I converting enzyme 2	Rattus norvegicus	146-177
27533767-1	2016	The present study sought to determine cardiovascular effects of aerobic training associated with diminazene aceturate (DIZE), an activator of the angiotensin converting enzyme 2, in spontaneously hypertensive rats (SHRs).	diminazene aceturate	119-123	angiotensin I converting enzyme 2	Rattus norvegicus	146-177
25867182-5	2015	Diminazene aceturate treatment (15 mg/kg/day) activated ACE2, increased the circulating Ang (1-7) level, and augmented EDR and FMD in db/db mouse arteries.	diminazene aceturate	0-20	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	56-60
27153779-2	2016	Recent studies have shown that diminazene aceturate (DIZE) acts as an ACE2 activator.	diminazene aceturate	31-51	angiotensin I converting enzyme 2	Rattus norvegicus	70-74
27153779-2	2016	Recent studies have shown that diminazene aceturate (DIZE) acts as an ACE2 activator.	diminazene aceturate	53-57	angiotensin I converting enzyme 2	Rattus norvegicus	70-74
26862037-0	2016	Angiotensin-converting enzyme 2 activator diminazene aceturate prevents lipopolysaccharide-induced inflammation by inhibiting MAPK and NF-kappaB pathways in human retinal pigment epithelium.	diminazene aceturate	42-62	nuclear factor kappa B subunit 1	Homo sapiens	135-144
26862037-4	2016	We investigated whether diminazene aceturate (DIZE), an angiotensin-converting enzyme 2 (ACE2) activator, prevented lipopolysaccharide (LPS)-induced inflammatory response by activating the protective axis and whether the effect was mediated by inhibiting the mitogen-activated protein kinase (MAPK) and the nuclear factor-kappaB (NF-kappaB) pathways.	diminazene aceturate	24-44	angiotensin converting enzyme 2	Homo sapiens	56-87
26862037-4	2016	We investigated whether diminazene aceturate (DIZE), an angiotensin-converting enzyme 2 (ACE2) activator, prevented lipopolysaccharide (LPS)-induced inflammatory response by activating the protective axis and whether the effect was mediated by inhibiting the mitogen-activated protein kinase (MAPK) and the nuclear factor-kappaB (NF-kappaB) pathways.	diminazene aceturate	24-44	angiotensin converting enzyme 2	Homo sapiens	89-93
26862037-4	2016	We investigated whether diminazene aceturate (DIZE), an angiotensin-converting enzyme 2 (ACE2) activator, prevented lipopolysaccharide (LPS)-induced inflammatory response by activating the protective axis and whether the effect was mediated by inhibiting the mitogen-activated protein kinase (MAPK) and the nuclear factor-kappaB (NF-kappaB) pathways.	diminazene aceturate	46-50	angiotensin converting enzyme 2	Homo sapiens	56-87
26862037-4	2016	We investigated whether diminazene aceturate (DIZE), an angiotensin-converting enzyme 2 (ACE2) activator, prevented lipopolysaccharide (LPS)-induced inflammatory response by activating the protective axis and whether the effect was mediated by inhibiting the mitogen-activated protein kinase (MAPK) and the nuclear factor-kappaB (NF-kappaB) pathways.	diminazene aceturate	46-50	angiotensin converting enzyme 2	Homo sapiens	89-93
26458404-0	2016	Anti-hypertensive Effects of Diminazene Aceturate: An Angiotensin- Converting Enzyme 2 Activator in Rats.	diminazene aceturate	29-49	angiotensin I converting enzyme 2	Rattus norvegicus	54-86
26458404-2	2016	Recently, a new ACE2 activator, named diminazene aceturate (DIZE), was described.	diminazene aceturate	38-58	angiotensin I converting enzyme 2	Rattus norvegicus	16-20
26458404-2	2016	Recently, a new ACE2 activator, named diminazene aceturate (DIZE), was described.	diminazene aceturate	60-64	angiotensin I converting enzyme 2	Rattus norvegicus	16-20
26862037-0	2016	Angiotensin-converting enzyme 2 activator diminazene aceturate prevents lipopolysaccharide-induced inflammation by inhibiting MAPK and NF-kappaB pathways in human retinal pigment epithelium.	diminazene aceturate	42-62	angiotensin converting enzyme 2	Homo sapiens	0-31
26204514-0	2015	Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats.	diminazene aceturate	87-107	angiotensin I converting enzyme 2	Rattus norvegicus	44-75
26204514-1	2015	The aim of this study was to develop and evaluate the effects of chitosan inserts for sustained release of the angiotensin-converting enzyme 2 (ACE2) activator, diminazene aceturate (DIZE), in experimental glaucoma.	diminazene aceturate	161-181	angiotensin I converting enzyme 2	Rattus norvegicus	111-142
26204514-1	2015	The aim of this study was to develop and evaluate the effects of chitosan inserts for sustained release of the angiotensin-converting enzyme 2 (ACE2) activator, diminazene aceturate (DIZE), in experimental glaucoma.	diminazene aceturate	161-181	angiotensin I converting enzyme 2	Rattus norvegicus	144-148
26204514-1	2015	The aim of this study was to develop and evaluate the effects of chitosan inserts for sustained release of the angiotensin-converting enzyme 2 (ACE2) activator, diminazene aceturate (DIZE), in experimental glaucoma.	diminazene aceturate	183-187	angiotensin I converting enzyme 2	Rattus norvegicus	111-142
26204514-1	2015	The aim of this study was to develop and evaluate the effects of chitosan inserts for sustained release of the angiotensin-converting enzyme 2 (ACE2) activator, diminazene aceturate (DIZE), in experimental glaucoma.	diminazene aceturate	183-187	angiotensin I converting enzyme 2	Rattus norvegicus	144-148
26110416-7	2015	Treatment of infected mice with Berenil, a trypanocidal drug, restored the development of CIA-associated clinical symptoms.	diminazene aceturate	32-39	nuclear receptor coactivator 5	Mus musculus	90-93
24741027-3	2014	The present study aimed to evaluate whether an angiotensin-converting enzyme 2 (ACE2) activator, diminazene aceturate (DIZE), could improve the streptozotocin (STZ)-induced electrical changes in ventricular repolarization in hyperglycaemic rats.	diminazene aceturate	97-117	angiotensin I converting enzyme 2	Rattus norvegicus	47-78
25786223-0	2015	Short-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 activity in rats with subtotal nephrectomy.	diminazene aceturate	26-46	angiotensin I converting enzyme 2	Rattus norvegicus	83-87
25786223-3	2015	This study assessed the effect of diminazine aceturate (DIZE), which has been described as an ACE2 activator, on kidney ACE2 mRNA and activity in rats with kidney injury due to subtotal nephrectomy (STNx).	diminazene aceturate	34-54	angiotensin I converting enzyme 2	Rattus norvegicus	94-98
25786223-3	2015	This study assessed the effect of diminazine aceturate (DIZE), which has been described as an ACE2 activator, on kidney ACE2 mRNA and activity in rats with kidney injury due to subtotal nephrectomy (STNx).	diminazene aceturate	34-54	angiotensin I converting enzyme 2	Rattus norvegicus	120-124
25786223-3	2015	This study assessed the effect of diminazine aceturate (DIZE), which has been described as an ACE2 activator, on kidney ACE2 mRNA and activity in rats with kidney injury due to subtotal nephrectomy (STNx).	diminazene aceturate	56-60	angiotensin I converting enzyme 2	Rattus norvegicus	94-98
25786223-3	2015	This study assessed the effect of diminazine aceturate (DIZE), which has been described as an ACE2 activator, on kidney ACE2 mRNA and activity in rats with kidney injury due to subtotal nephrectomy (STNx).	diminazene aceturate	56-60	angiotensin I converting enzyme 2	Rattus norvegicus	120-124
25666042-3	2015	In this study, 12 weeks old male mice were treated with the ACE 2 activator (diminazene aceturate, DIZE, 1 mg/kg/day, gavage) or saline (control) for 30 days followed by glucose tolerance tests, insulin sensitivity tests, and blood analysis.	diminazene aceturate	77-97	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	60-65
25301841-9	2014	ACE2 activation by administration of diminazene aceturate (30 mg/kg per day) to Ldlr(-/-) mice increased kidney ACE2 mRNA abundance and activity and elevated plasma Ang-(1-7) concentrations.	diminazene aceturate	37-57	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	0-4
25301841-9	2014	ACE2 activation by administration of diminazene aceturate (30 mg/kg per day) to Ldlr(-/-) mice increased kidney ACE2 mRNA abundance and activity and elevated plasma Ang-(1-7) concentrations.	diminazene aceturate	37-57	low density lipoprotein receptor	Mus musculus	80-84
25301841-9	2014	ACE2 activation by administration of diminazene aceturate (30 mg/kg per day) to Ldlr(-/-) mice increased kidney ACE2 mRNA abundance and activity and elevated plasma Ang-(1-7) concentrations.	diminazene aceturate	37-57	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	112-116
25301841-11	2014	Notably, diminazene aceturate significantly decreased aortic lumen diameters and aortic external diameters of AngII-infused mice resulting in a marked reduction in AAA incidence (from 73% to 29%).	diminazene aceturate	9-29	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	110-115
25883526-1	2015	PURPOSE: Our previous study demonstrated that an intraperitoneal injection of Diminazene Aceturate (DIZE) attenuated uveitis by activating ocular angiotensin-converting enzyme 2 (ACE2).	diminazene aceturate	78-98	angiotensin converting enzyme 2	Homo sapiens	146-177
25883526-1	2015	PURPOSE: Our previous study demonstrated that an intraperitoneal injection of Diminazene Aceturate (DIZE) attenuated uveitis by activating ocular angiotensin-converting enzyme 2 (ACE2).	diminazene aceturate	78-98	angiotensin converting enzyme 2	Homo sapiens	179-183
25883526-1	2015	PURPOSE: Our previous study demonstrated that an intraperitoneal injection of Diminazene Aceturate (DIZE) attenuated uveitis by activating ocular angiotensin-converting enzyme 2 (ACE2).	diminazene aceturate	100-104	angiotensin converting enzyme 2	Homo sapiens	146-177
25883526-1	2015	PURPOSE: Our previous study demonstrated that an intraperitoneal injection of Diminazene Aceturate (DIZE) attenuated uveitis by activating ocular angiotensin-converting enzyme 2 (ACE2).	diminazene aceturate	100-104	angiotensin converting enzyme 2	Homo sapiens	179-183
24741027-3	2014	The present study aimed to evaluate whether an angiotensin-converting enzyme 2 (ACE2) activator, diminazene aceturate (DIZE), could improve the streptozotocin (STZ)-induced electrical changes in ventricular repolarization in hyperglycaemic rats.	diminazene aceturate	97-117	angiotensin I converting enzyme 2	Rattus norvegicus	80-84
24741027-3	2014	The present study aimed to evaluate whether an angiotensin-converting enzyme 2 (ACE2) activator, diminazene aceturate (DIZE), could improve the streptozotocin (STZ)-induced electrical changes in ventricular repolarization in hyperglycaemic rats.	diminazene aceturate	119-123	angiotensin I converting enzyme 2	Rattus norvegicus	47-78
24741027-3	2014	The present study aimed to evaluate whether an angiotensin-converting enzyme 2 (ACE2) activator, diminazene aceturate (DIZE), could improve the streptozotocin (STZ)-induced electrical changes in ventricular repolarization in hyperglycaemic rats.	diminazene aceturate	119-123	angiotensin I converting enzyme 2	Rattus norvegicus	80-84
24179040-4	2014	We show that pre-treatment of macrophages with Berenil dramatically suppressed IL-6, IL-12 and TNF-alpha production following LPS, CpG and Poly I:C stimulation without altering the expression of TLRs.	diminazene aceturate	47-54	interleukin 6	Mus musculus	79-83
24179040-4	2014	We show that pre-treatment of macrophages with Berenil dramatically suppressed IL-6, IL-12 and TNF-alpha production following LPS, CpG and Poly I:C stimulation without altering the expression of TLRs.	diminazene aceturate	47-54	tumor necrosis factor	Mus musculus	95-104
24179040-6	2014	Interestingly, Berenil treatment up-regulated the phosphorylation of STAT5 and the expression of suppressor of cytokine signaling 1 (SOCS1) and SOCS3, which are negative regulators of innate immune responses, including MAPKs and STATs.	diminazene aceturate	15-22	signal transducer and activator of transcription 5A	Mus musculus	69-74
24179040-6	2014	Interestingly, Berenil treatment up-regulated the phosphorylation of STAT5 and the expression of suppressor of cytokine signaling 1 (SOCS1) and SOCS3, which are negative regulators of innate immune responses, including MAPKs and STATs.	diminazene aceturate	15-22	suppressor of cytokine signaling 1	Mus musculus	97-131
24179040-6	2014	Interestingly, Berenil treatment up-regulated the phosphorylation of STAT5 and the expression of suppressor of cytokine signaling 1 (SOCS1) and SOCS3, which are negative regulators of innate immune responses, including MAPKs and STATs.	diminazene aceturate	15-22	suppressor of cytokine signaling 1	Mus musculus	133-138
24179040-6	2014	Interestingly, Berenil treatment up-regulated the phosphorylation of STAT5 and the expression of suppressor of cytokine signaling 1 (SOCS1) and SOCS3, which are negative regulators of innate immune responses, including MAPKs and STATs.	diminazene aceturate	15-22	suppressor of cytokine signaling 3	Mus musculus	144-149
24179040-6	2014	Interestingly, Berenil treatment up-regulated the phosphorylation of STAT5 and the expression of suppressor of cytokine signaling 1 (SOCS1) and SOCS3, which are negative regulators of innate immune responses, including MAPKs and STATs.	diminazene aceturate	15-22	signal transducer and activator of transcription 1	Mus musculus	229-234
24578214-6	2014	In addition, synovial fibroblasts were treated with diminazene aceturate (DA), an inhibitor of SSAT-1.	diminazene aceturate	52-72	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	95-101
24578214-6	2014	In addition, synovial fibroblasts were treated with diminazene aceturate (DA), an inhibitor of SSAT-1.	diminazene aceturate	74-76	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	95-101
24954860-10	2014	Incubation of examined cells with the berenil-platinum (II) complexes also led to the increase in the levels of active caspases 3, 8 and 9.	diminazene aceturate	38-45	caspase 3	Homo sapiens	119-138
25478235-3	2014	This study was designed to evaluate the effects of activation endogenous ACE2 using the diminazene aceturate (DIZE) in renal I/R injury in male and female rats.	diminazene aceturate	88-108	angiotensin I converting enzyme 2	Rattus norvegicus	73-77
25478235-3	2014	This study was designed to evaluate the effects of activation endogenous ACE2 using the diminazene aceturate (DIZE) in renal I/R injury in male and female rats.	diminazene aceturate	110-114	angiotensin I converting enzyme 2	Rattus norvegicus	73-77
24854854-0	2014	Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice.	diminazene aceturate	49-69	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	0-31
24854854-0	2014	Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice.	diminazene aceturate	49-69	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	33-37
24854854-5	2014	METHODS: ACE2 activator diminazene aceturate (DIZE) was administered both systemically and locally.	diminazene aceturate	24-44	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	9-13
24854854-5	2014	METHODS: ACE2 activator diminazene aceturate (DIZE) was administered both systemically and locally.	diminazene aceturate	46-50	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	9-13
24390175-2	2014	This in vitro study compared the direct and indirect effects of angiotensin-(1-7), the ACE1 inhibitor captopril, and diminazene aceturate (DIZE) an alleged ACE2 activator in rings of porcine coronary arteries, by measuring changes of isometric tension.	diminazene aceturate	117-137	angiotensin converting enzyme 2	Homo sapiens	156-160
24390175-2	2014	This in vitro study compared the direct and indirect effects of angiotensin-(1-7), the ACE1 inhibitor captopril, and diminazene aceturate (DIZE) an alleged ACE2 activator in rings of porcine coronary arteries, by measuring changes of isometric tension.	diminazene aceturate	139-143	angiotensin converting enzyme 2	Homo sapiens	156-160
23909602-0	2013	Biochemical responses of Anticarsia gemmatalis (Lepidoptera: Noctuidae) in soybean cultivars sprayed with the protease inhibitor berenil.	diminazene aceturate	129-136	protease inhibitor	Glycine max	110-128
23959549-0	2013	Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology.	diminazene aceturate	0-20	angiotensin I converting enzyme 2	Rattus norvegicus	30-61
23959549-3	2013	Diminazene aceturate (DIZE), a small molecule ACE2 activator, has been used to evaluate this hypothesis.	diminazene aceturate	0-20	angiotensin I converting enzyme 2	Rattus norvegicus	46-50
23959549-3	2013	Diminazene aceturate (DIZE), a small molecule ACE2 activator, has been used to evaluate this hypothesis.	diminazene aceturate	22-26	angiotensin I converting enzyme 2	Rattus norvegicus	46-50
23702784-1	2013	PURPOSE: To evaluate the effects of the activation of endogenous angiotensin-converting enzyme 2 (ACE2) using the compound diminazene aceturate (DIZE) in an experimental model of glaucoma in Wistar rats.	diminazene aceturate	123-143	angiotensin I converting enzyme 2	Rattus norvegicus	65-96
23702784-1	2013	PURPOSE: To evaluate the effects of the activation of endogenous angiotensin-converting enzyme 2 (ACE2) using the compound diminazene aceturate (DIZE) in an experimental model of glaucoma in Wistar rats.	diminazene aceturate	145-149	angiotensin I converting enzyme 2	Rattus norvegicus	65-96
19764817-7	2009	The structures of two inhibitor complexes of hDAO, berenil and pentamidine, have been refined to resolutions of 2.1 and 2.2 A, respectively.	diminazene aceturate	51-58	D-amino acid oxidase	Homo sapiens	45-49
23370913-2	2013	Recently, an antitrypanosomal drug, diminazene aceturate (DIZE), was shown to exert an "off-target" effect of enhancing the enzymatic activity of ACE2 in vitro.	diminazene aceturate	36-56	angiotensin I converting enzyme 2	Rattus norvegicus	146-150
23370913-2	2013	Recently, an antitrypanosomal drug, diminazene aceturate (DIZE), was shown to exert an "off-target" effect of enhancing the enzymatic activity of ACE2 in vitro.	diminazene aceturate	58-62	angiotensin I converting enzyme 2	Rattus norvegicus	146-150
21685445-4	2011	The results of the present study demonstrated that intracerebroventricular infusion of either Ang-(1-7) or an ACE2 activator, diminazine aceturate (DIZE), prior to and following ET-1-induced MCAO significantly attenuated the cerebral infarct size and neurological deficits measured 72 h after the insult.	diminazene aceturate	126-146	angiotensin converting enzyme 2	Homo sapiens	110-114
21685445-4	2011	The results of the present study demonstrated that intracerebroventricular infusion of either Ang-(1-7) or an ACE2 activator, diminazine aceturate (DIZE), prior to and following ET-1-induced MCAO significantly attenuated the cerebral infarct size and neurological deficits measured 72 h after the insult.	diminazene aceturate	126-146	endothelin 1	Homo sapiens	178-182
21685445-4	2011	The results of the present study demonstrated that intracerebroventricular infusion of either Ang-(1-7) or an ACE2 activator, diminazine aceturate (DIZE), prior to and following ET-1-induced MCAO significantly attenuated the cerebral infarct size and neurological deficits measured 72 h after the insult.	diminazene aceturate	148-152	angiotensin converting enzyme 2	Homo sapiens	110-114
23230080-5	2013	ACE2 expression was lower, and ACE2 activators xanthenone and diminazine aceturate were less effective in inducing the migration in cells from patients with diabetes compared with controls.	diminazene aceturate	62-82	angiotensin converting enzyme 2	Homo sapiens	31-35
15120899-8	2004	Especially, the fact concerning Apo-E that could be detected when the particles were incubated in human serum is absent after the mouse serum incubation, potentially, is a critical point for the delivery via the LDL-uptake mechanism but the data demonstrate that LDC nanoparticles, with 33% (wt/wt) drug loading capacity possess the potential to act as a delivery system for hydrophilic drugs like diminazene diaceturate and that further studies have to demonstrate the usability as a brain delivery system.	diminazene aceturate	398-420	apolipoprotein E	Homo sapiens	32-37
15634403-3	2004	METHODS: The plasmids containing the shRNA of AT(1)R were constructed, and transfected vascular smooth muscle cell (VSMC) to detect the effect on the AT(1)R expression by RT-PCR and Western blot, observe the shape of VSMCs by the inverted phase contrast microscope, and detect the hyperplasia of VSMCs by trypan blues staining and MTT.	diminazene aceturate	305-311	angiotensin II receptor, type 1a	Rattus norvegicus	46-52
21192420-3	2004	METHODS: The plasmids containing the shRNA of AT1R were constructed, and transfected vascular smooth muscle cell (VSMC) to detect the effect on the AT1R expression by RT-PCR and Western blot, and detect the hyperplasia of VSMCs by trypan blues training and MTT.	diminazene aceturate	231-237	angiotensin II receptor, type 1b	Rattus norvegicus	46-50
11734561-9	2002	In addition, ADOMETDC overproduction in wild type parasites alleviated the toxic effects of 5"-(((Z)-4-amino-2-butenyl)methylamino)-5"-deoxyadenosine (MDL 73811), but not pentamidine, berenil, or methylglyoxyl bis(guanylhydrazone), all inhibitors of ADOMETDC activities in vitro.	diminazene aceturate	184-191	S-adenosylmethionine decarboxylase	Leishmania donovani	13-21
12475232-4	2002	The multicyclic dyes Hoechst 33258, DAPI, and berenil bind to TAR RNA in a similar manner and gave nearly identical signatures.	diminazene aceturate	46-53	RNA binding motif protein 8A	Homo sapiens	62-65
14526167-3	2003	Following optimal treatment with 150 microg/ml berenil 24 h prior to fixation, the heterozygote frequency of FRA16B is found to be about 5% in populations of European descent.	diminazene aceturate	47-54	fragile site, distamycin A type, rare, fra(16)(q22.1)	Homo sapiens	109-115
11267928-4	2001	Treatment of mice on day 21 with a subcurative dose of diminazene aceturate (Berenil), a procedure known to induce a mild PTRE, cleared the parasite from the circulation with plasma APP and liver expression of mRNA for IL-6 and TNFalpha returning to the levels in the controls.	diminazene aceturate	55-75	interleukin 6	Mus musculus	219-223
11267928-4	2001	Treatment of mice on day 21 with a subcurative dose of diminazene aceturate (Berenil), a procedure known to induce a mild PTRE, cleared the parasite from the circulation with plasma APP and liver expression of mRNA for IL-6 and TNFalpha returning to the levels in the controls.	diminazene aceturate	55-75	tumor necrosis factor	Mus musculus	228-236
11267928-4	2001	Treatment of mice on day 21 with a subcurative dose of diminazene aceturate (Berenil), a procedure known to induce a mild PTRE, cleared the parasite from the circulation with plasma APP and liver expression of mRNA for IL-6 and TNFalpha returning to the levels in the controls.	diminazene aceturate	77-84	interleukin 6	Mus musculus	219-223
11267928-4	2001	Treatment of mice on day 21 with a subcurative dose of diminazene aceturate (Berenil), a procedure known to induce a mild PTRE, cleared the parasite from the circulation with plasma APP and liver expression of mRNA for IL-6 and TNFalpha returning to the levels in the controls.	diminazene aceturate	77-84	tumor necrosis factor	Mus musculus	228-236
11267928-6	2001	A further subcurative dose of Berenil, leading to a more severe PTRE, was associated with elevated serum concentrations of Hp and SAP, increased TNFalpha mRNA in the liver and detectable IL-6 and TNFalpha mRNA in the brain.	diminazene aceturate	30-37	tumor necrosis factor	Mus musculus	145-153
11267928-6	2001	A further subcurative dose of Berenil, leading to a more severe PTRE, was associated with elevated serum concentrations of Hp and SAP, increased TNFalpha mRNA in the liver and detectable IL-6 and TNFalpha mRNA in the brain.	diminazene aceturate	30-37	interleukin 6	Mus musculus	187-191
11267928-6	2001	A further subcurative dose of Berenil, leading to a more severe PTRE, was associated with elevated serum concentrations of Hp and SAP, increased TNFalpha mRNA in the liver and detectable IL-6 and TNFalpha mRNA in the brain.	diminazene aceturate	30-37	tumor necrosis factor	Mus musculus	196-204
10598570-3	1999	We document two unrelated normal individuals who are homozygotes for the rare fragile site FRA16B and record the patterns of induction of this fragile site with berenil.	diminazene aceturate	161-168	fragile site, distamycin A type, rare, fra(16)(q22.1)	Homo sapiens	91-97
9561493-0	1997	The effect of diminazene aceturate on cholinesterase activity in dogs with canine babesiosis.	diminazene aceturate	14-34	butyrylcholinesterase	Canis lupus familiaris	38-52
8224368-2	1993	Berenil, administered to rats in vivo, promoted a decrease in liver SAMDC activity, but an increase in ODC and SAT activity.	diminazene aceturate	0-7	adenosylmethionine decarboxylase 1	Rattus norvegicus	68-73
8628678-5	1996	The ELD data show that the mode of binding of the drugs Hoechst 33258, berenil and DAPI to the TAR RNA is similar to their binding mode in GC-rich regions of DNA and likely involves intercalation into the A-form TAR RNA helix.	diminazene aceturate	71-78	RNA binding motif protein 8A	Homo sapiens	95-98
8628678-5	1996	The ELD data show that the mode of binding of the drugs Hoechst 33258, berenil and DAPI to the TAR RNA is similar to their binding mode in GC-rich regions of DNA and likely involves intercalation into the A-form TAR RNA helix.	diminazene aceturate	71-78	RNA binding motif protein 8A	Homo sapiens	212-215
8573565-1	1996	We have used DNase I footprinting and gel shift assays to characterize the interaction of DNA binding drugs mithramycin, distamycin, and berenil with an intermolecular triplex formed by the human c-Ki-ras promoter.	diminazene aceturate	137-144	KRAS proto-oncogene, GTPase	Homo sapiens	196-204
8573565-8	1996	Berenil does not bind within the triplex target sequence, and only one berenil binding sequence downstream of the triplex motif was present within the c-Ki-ras promoter fragment.	diminazene aceturate	71-78	KRAS proto-oncogene, GTPase	Homo sapiens	151-159
8262923-8	1993	Berenil (4,4"-diazoamino-bis-benzamidine), a parabolic competitive inhibitor of beta-trypsin, was a hyperbolic competitive inhibitor of azo-beta-trypsin.	diminazene aceturate	0-7	serine protease 1	Bos taurus	80-92
8262923-8	1993	Berenil (4,4"-diazoamino-bis-benzamidine), a parabolic competitive inhibitor of beta-trypsin, was a hyperbolic competitive inhibitor of azo-beta-trypsin.	diminazene aceturate	0-7	serine protease 1	Bos taurus	140-152
9223132-3	1997	Female CD-1 mice infected with an eflornithine-resistant trypanosome stabilate and treated with the trypanocidal compound diminazene aceturate on or after day 21 post-infection develop a reactive encephalopathy and relapsing parasitaemia.	diminazene aceturate	122-142	CD1 antigen complex	Mus musculus	7-11
7880838-8	1995	Competitive electrophoretic mobility shift assays were used to show that berenil, distamycin, and mithramycin, all of which bind in the minor groove, compete with MBP-1 for binding to the MPB-1 binding site.	diminazene aceturate	73-80	mannose binding lectin 2	Homo sapiens	163-168
7880838-8	1995	Competitive electrophoretic mobility shift assays were used to show that berenil, distamycin, and mithramycin, all of which bind in the minor groove, compete with MBP-1 for binding to the MPB-1 binding site.	diminazene aceturate	73-80	enolase 1	Homo sapiens	188-193
8224368-2	1993	Berenil, administered to rats in vivo, promoted a decrease in liver SAMDC activity, but an increase in ODC and SAT activity.	diminazene aceturate	0-7	ornithine decarboxylase 1	Rattus norvegicus	103-106
8224368-7	1993	Adrenergic antagonists counteracted the effect of Berenil on ODC activity.	diminazene aceturate	50-57	ornithine decarboxylase 1	Rattus norvegicus	61-64
1864598-4	1991	An increased expression of fra(16)(p12) was found following treatment with Hoechst 33258 or berenil, but not with distamycin A.	diminazene aceturate	92-99	DNA polymerase epsilon 4, accessory subunit	Homo sapiens	35-38
1510731-1	1992	Pentamidine and berenil, clinical antiparasitic amidines, have been found to be potent competitive inhibitors of human spermidine/spermine acetyltransferase (SSAT).	diminazene aceturate	16-23	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	119-156
1510731-1	1992	Pentamidine and berenil, clinical antiparasitic amidines, have been found to be potent competitive inhibitors of human spermidine/spermine acetyltransferase (SSAT).	diminazene aceturate	16-23	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	158-162
1864598-8	1991	An increased frequency of sister chromatid exchanges was observed at fra(16)(p12) following simultaneous treatment with BrdUrd and berenil, mainly when the site was expressed as an isochromatid gap.	diminazene aceturate	131-138	DNA polymerase epsilon 4, accessory subunit	Homo sapiens	77-80
34739541-3	2021	Some denervated mice were treated with Ang 1-7 or diminazene aceturate (DIZE), an ACE2 activator, to increase Ang 1-7 levels.	diminazene aceturate	50-70	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	82-86
1991117-14	1991	The berenil molecule binds at the 5"-AAT (identical to 5"-ATT on the complementary strand) site such that (i) favorable hydrogen bonds are formed between the charged amidinium groups and the N3 atoms of Ado 6 and Ado 18 and (ii) the ligand is closely isohelical with the floor of the minor groove.	diminazene aceturate	4-11	serpin family A member 1	Homo sapiens	37-40
34739541-3	2021	Some denervated mice were treated with Ang 1-7 or diminazene aceturate (DIZE), an ACE2 activator, to increase Ang 1-7 levels.	diminazene aceturate	50-70	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	110-117
34739541-3	2021	Some denervated mice were treated with Ang 1-7 or diminazene aceturate (DIZE), an ACE2 activator, to increase Ang 1-7 levels.	diminazene aceturate	72-76	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	82-86
34739541-3	2021	Some denervated mice were treated with Ang 1-7 or diminazene aceturate (DIZE), an ACE2 activator, to increase Ang 1-7 levels.	diminazene aceturate	72-76	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	110-117
34529881-4	2021	We found that repeated lipopolysaccharide (LPS) treatment shifted the balance between ACE/Ang II/AT1 and ACE2/Ang(1-7)/MasR axis to the deleterious side and treatment with either MasR agonist, AVE0991 (AVE) or ACE2 activator, diminazene aceturate, exhibited strong neuroprotective actions.	diminazene aceturate	226-246	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	210-214
35533351-6	2022	DIZE exerted its effect by activating ACE2 that produced Ang (1-7), a neuroprotective peptide.	diminazene aceturate	0-4	angiotensin I converting enzyme 2	Rattus norvegicus	38-42
34712133-0	2021	Diminazen Aceturate Protects Pulmonary Ischemia-Reperfusion Injury via Inhibition of ADAM17-Mediated Angiotensin-Converting Enzyme 2 Shedding.	diminazene aceturate	0-19	ADAM metallopeptidase domain 17	Homo sapiens	85-91
34712133-0	2021	Diminazen Aceturate Protects Pulmonary Ischemia-Reperfusion Injury via Inhibition of ADAM17-Mediated Angiotensin-Converting Enzyme 2 Shedding.	diminazene aceturate	0-19	angiotensin converting enzyme 2	Homo sapiens	101-132
34712133-8	2021	Treatment with ACE2 protectant diminazen aceturate (DIZE) maintained higher ACE2 enzyme activity and reduced angiotensin II, angiotensin type 1 receptor, and ADAM17 levels in the lung tissue.	diminazene aceturate	31-50	angiotensin converting enzyme 2	Homo sapiens	15-19
34712133-8	2021	Treatment with ACE2 protectant diminazen aceturate (DIZE) maintained higher ACE2 enzyme activity and reduced angiotensin II, angiotensin type 1 receptor, and ADAM17 levels in the lung tissue.	diminazene aceturate	31-50	angiotensin converting enzyme 2	Homo sapiens	76-80
34712133-8	2021	Treatment with ACE2 protectant diminazen aceturate (DIZE) maintained higher ACE2 enzyme activity and reduced angiotensin II, angiotensin type 1 receptor, and ADAM17 levels in the lung tissue.	diminazene aceturate	31-50	angiotensinogen	Homo sapiens	109-123
34712133-8	2021	Treatment with ACE2 protectant diminazen aceturate (DIZE) maintained higher ACE2 enzyme activity and reduced angiotensin II, angiotensin type 1 receptor, and ADAM17 levels in the lung tissue.	diminazene aceturate	31-50	ADAM metallopeptidase domain 17	Homo sapiens	158-164
34712133-8	2021	Treatment with ACE2 protectant diminazen aceturate (DIZE) maintained higher ACE2 enzyme activity and reduced angiotensin II, angiotensin type 1 receptor, and ADAM17 levels in the lung tissue.	diminazene aceturate	52-56	angiotensin converting enzyme 2	Homo sapiens	15-19
34712133-8	2021	Treatment with ACE2 protectant diminazen aceturate (DIZE) maintained higher ACE2 enzyme activity and reduced angiotensin II, angiotensin type 1 receptor, and ADAM17 levels in the lung tissue.	diminazene aceturate	52-56	angiotensin converting enzyme 2	Homo sapiens	76-80
34712133-8	2021	Treatment with ACE2 protectant diminazen aceturate (DIZE) maintained higher ACE2 enzyme activity and reduced angiotensin II, angiotensin type 1 receptor, and ADAM17 levels in the lung tissue.	diminazene aceturate	52-56	angiotensinogen	Homo sapiens	109-123
34712133-8	2021	Treatment with ACE2 protectant diminazen aceturate (DIZE) maintained higher ACE2 enzyme activity and reduced angiotensin II, angiotensin type 1 receptor, and ADAM17 levels in the lung tissue.	diminazene aceturate	52-56	ADAM metallopeptidase domain 17	Homo sapiens	158-164
34712133-9	2021	Concurrently, DIZE-inhibited oxidative stress and nitrosative stress via p38MAPK and NF-kappaB pathways consequently reduced release of pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-1beta.	diminazene aceturate	14-18	tumor necrosis factor	Homo sapiens	171-180
34712133-9	2021	Concurrently, DIZE-inhibited oxidative stress and nitrosative stress via p38MAPK and NF-kappaB pathways consequently reduced release of pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-1beta.	diminazene aceturate	14-18	interleukin 6	Homo sapiens	182-186
34712133-9	2021	Concurrently, DIZE-inhibited oxidative stress and nitrosative stress via p38MAPK and NF-kappaB pathways consequently reduced release of pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-1beta.	diminazene aceturate	14-18	interleukin 1 alpha	Homo sapiens	192-200
34712133-11	2021	We concluded that DIZE protects the lungs from IR injury via inhibition of ADAM17-mediated ACE2 shedding.	diminazene aceturate	18-22	ADAM metallopeptidase domain 17	Homo sapiens	75-81
34712133-11	2021	We concluded that DIZE protects the lungs from IR injury via inhibition of ADAM17-mediated ACE2 shedding.	diminazene aceturate	18-22	angiotensin converting enzyme 2	Homo sapiens	91-95
35199858-0	2022	Challenges with the proposed ACE2 activation mechanism of diminazene aceturate.	diminazene aceturate	58-78	angiotensin converting enzyme 2	Homo sapiens	29-33
34070749-0	2021	Diminazene Aceturate Stabilizes Atherosclerotic Plaque and Attenuates Hepatic Steatosis in apoE-Knockout Mice by Influencing Macrophages Polarization and Taurine Biosynthesis.	diminazene aceturate	0-20	apolipoprotein E	Mus musculus	91-95
34070749-4	2021	Therefore, the aim of our study was to comprehensively evaluate the influence of prolonged treatment with ACE2 activator, diminazene aceturate (DIZE) on the development of atherosclerotic lesions and hepatic steatosis in apoE-/- mice fed a high-fat diet (HFD).	diminazene aceturate	122-142	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	106-110
34070749-4	2021	Therefore, the aim of our study was to comprehensively evaluate the influence of prolonged treatment with ACE2 activator, diminazene aceturate (DIZE) on the development of atherosclerotic lesions and hepatic steatosis in apoE-/- mice fed a high-fat diet (HFD).	diminazene aceturate	122-142	apolipoprotein E	Mus musculus	221-225
34070749-4	2021	Therefore, the aim of our study was to comprehensively evaluate the influence of prolonged treatment with ACE2 activator, diminazene aceturate (DIZE) on the development of atherosclerotic lesions and hepatic steatosis in apoE-/- mice fed a high-fat diet (HFD).	diminazene aceturate	144-148	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	106-110
35347063-5	2022	ACE2 activator diminazene aceturate (DIZE) significantly reduced pulmonary fibrosis, decreased alpha-SMA expression, collagen I, hydroxyproline, and TGF-beta1 in the lung.	diminazene aceturate	15-35	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	0-4
35347063-5	2022	ACE2 activator diminazene aceturate (DIZE) significantly reduced pulmonary fibrosis, decreased alpha-SMA expression, collagen I, hydroxyproline, and TGF-beta1 in the lung.	diminazene aceturate	15-35	actin alpha 2, smooth muscle, aorta	Mus musculus	95-104
35347063-5	2022	ACE2 activator diminazene aceturate (DIZE) significantly reduced pulmonary fibrosis, decreased alpha-SMA expression, collagen I, hydroxyproline, and TGF-beta1 in the lung.	diminazene aceturate	15-35	transforming growth factor, beta 1	Mus musculus	149-158
35347063-5	2022	ACE2 activator diminazene aceturate (DIZE) significantly reduced pulmonary fibrosis, decreased alpha-SMA expression, collagen I, hydroxyproline, and TGF-beta1 in the lung.	diminazene aceturate	37-41	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	0-4
35347063-5	2022	ACE2 activator diminazene aceturate (DIZE) significantly reduced pulmonary fibrosis, decreased alpha-SMA expression, collagen I, hydroxyproline, and TGF-beta1 in the lung.	diminazene aceturate	37-41	actin alpha 2, smooth muscle, aorta	Mus musculus	95-104
35347063-5	2022	ACE2 activator diminazene aceturate (DIZE) significantly reduced pulmonary fibrosis, decreased alpha-SMA expression, collagen I, hydroxyproline, and TGF-beta1 in the lung.	diminazene aceturate	37-41	transforming growth factor, beta 1	Mus musculus	149-158
35347063-6	2022	DIZE significantly decreased TGF-beta1 expression and the activation of Smad2 and Smad3.	diminazene aceturate	0-4	transforming growth factor, beta 1	Mus musculus	29-38
35347063-6	2022	DIZE significantly decreased TGF-beta1 expression and the activation of Smad2 and Smad3.	diminazene aceturate	0-4	SMAD family member 2	Mus musculus	72-77
35347063-6	2022	DIZE significantly decreased TGF-beta1 expression and the activation of Smad2 and Smad3.	diminazene aceturate	0-4	SMAD family member 3	Mus musculus	82-87
35536587-11	2022	In addition, we observed that GW4869 (an inhibitor of sEV release) or diminazene aceturate (DIZE, an activator of ACE2) treatment could attenuate PM2.5 -induced cardiac dysfunction in vivo.	diminazene aceturate	70-90	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	114-118
35536587-11	2022	In addition, we observed that GW4869 (an inhibitor of sEV release) or diminazene aceturate (DIZE, an activator of ACE2) treatment could attenuate PM2.5 -induced cardiac dysfunction in vivo.	diminazene aceturate	92-96	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	114-118
35533351-6	2022	DIZE exerted its effect by activating ACE2 that produced Ang (1-7), a neuroprotective peptide.	diminazene aceturate	0-4	angiogenin	Rattus norvegicus	57-65
2612695-2	1989	At concentration of proteinase as high as 10 micrograms/ml, the percentage of trypan-stained lymphocytes increase with enzyme level.	diminazene aceturate	78-84	endogenous retrovirus group K member 25	Homo sapiens	20-30
34861788-9	2022	Administration of ACE2 enzyme activator diminazene aceturate intraperitoneally rescued downregulation of ACE2 enzymatic activity and protein abundance in the brain.	diminazene aceturate	40-60	angiotensin converting enzyme 2	Homo sapiens	18-22
34861788-9	2022	Administration of ACE2 enzyme activator diminazene aceturate intraperitoneally rescued downregulation of ACE2 enzymatic activity and protein abundance in the brain.	diminazene aceturate	40-60	angiotensin converting enzyme 2	Homo sapiens	105-109
35369597-5	2022	Materials and Methods: Fluorescence-based SYBR Green I assay was used to evaluate CA"s inhibitory effect in vitro and in vivo when used either as a monotherapy or combined with diminazene aceturate (DA).	diminazene aceturate	177-197	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	82-84
35369597-5	2022	Materials and Methods: Fluorescence-based SYBR Green I assay was used to evaluate CA"s inhibitory effect in vitro and in vivo when used either as a monotherapy or combined with diminazene aceturate (DA).	diminazene aceturate	199-201	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	82-84
3759087-7	1986	The simultaneous treatment of lymphocytes with berenil and aphidicolin (inhibitor of DNA polymerase alpha) induces both the rare fra(16)(q22) and the common fra(16)(q23) within the same chromosome.	diminazene aceturate	47-54	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	85-105
3115268-0	1987	Inhibition of diamine oxidase of rat small intestine by pentamidine and berenil (diminazene aceturate).	diminazene aceturate	72-79	amine oxidase, copper containing 1	Rattus norvegicus	14-29
3115268-0	1987	Inhibition of diamine oxidase of rat small intestine by pentamidine and berenil (diminazene aceturate).	diminazene aceturate	81-101	amine oxidase, copper containing 1	Rattus norvegicus	14-29
3800910-5	1986	brucei AdoMet decarboxylase activity was apparently irreversibly inhibited in vitro by Berenil and reversibly by pentamidine and methylglyoxal bis(guanylhydrazone).	diminazene aceturate	87-94	methionine adenosyltransferase 1A	Rattus norvegicus	7-13
3800910-6	1986	Berenil also inhibited trypanosomal AdoMet decarboxylase by 70% within 4 h after administration to infected rats and markedly increased the concentration of putrescine in trypanosomes that were exposed to the drug in vivo.	diminazene aceturate	0-7	methionine adenosyltransferase 1A	Rattus norvegicus	36-42
3085681-0	1986	Inhibition of diamine oxidase and S-adenosylmethionine decarboxylase by diminacene aceturate (berenil).	diminazene aceturate	94-101	amine oxidase copper containing 1	Homo sapiens	14-29
4030626-6	1985	Hepatocytes in the vehicle groups took up more trypan when exposed to CCl4 than those treated with dmPGE2, stearic acid, or oleic acid at concentrations of 10(-9) to 10(-7) M. At 0.1% ethanol vehicle protected as well as all other treatments.	diminazene aceturate	47-53	C-C motif chemokine ligand 4	Rattus norvegicus	70-74
6348483-5	1983	Moreover, the accumulation of RD mutants in the presence of berenil, 5-fluorouracil and basic fuchsin was higher in the mmc1 than in MMC1 strains.	diminazene aceturate	60-67	Mps2p	Saccharomyces cerevisiae S288C	120-124
6734575-5	1984	However, a significant increase in cytosolic glutathione-S transferase was observed with Berenil.	diminazene aceturate	89-96	hematopoietic prostaglandin D synthase	Rattus norvegicus	45-70
6348483-5	1983	Moreover, the accumulation of RD mutants in the presence of berenil, 5-fluorouracil and basic fuchsin was higher in the mmc1 than in MMC1 strains.	diminazene aceturate	60-67	Mps2p	Saccharomyces cerevisiae S288C	133-137
33786714-7	2021	The primary tumor cells and pituitary cell lines (MMQ, GH3 and AtT-20/D16v-F2) were treated with diminazene aceturate (DIZE), an ACE2 agonist, with various dose regimens.	diminazene aceturate	97-117	angiotensin converting enzyme 2	Homo sapiens	129-133
33657582-4	2021	We also investigated the effects of Ang-(1-7) and the ACE-2 activator diminazene aceturate (DIZE) on aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) gene expression, in the absence or presence of the AT1R antagonist irbesartan, or of the MasR antagonist A779.	diminazene aceturate	70-90	cytochrome P450 family 11 subfamily B member 2	Homo sapiens	123-130
33684388-0	2021	Anti-diarrheal therapeutic potential of Diminazene Aceturate stimulation of the ACE II/Ang-(1-7)/Mas receptor axis in mice: a trial study.	diminazene aceturate	40-60	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	80-83
33684388-0	2021	Anti-diarrheal therapeutic potential of Diminazene Aceturate stimulation of the ACE II/Ang-(1-7)/Mas receptor axis in mice: a trial study.	diminazene aceturate	40-60	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	87-95
33684388-0	2021	Anti-diarrheal therapeutic potential of Diminazene Aceturate stimulation of the ACE II/Ang-(1-7)/Mas receptor axis in mice: a trial study.	diminazene aceturate	40-60	MAS1 oncogene	Mus musculus	97-109
33684388-4	2021	In this study, we aimed to evaluate the antidiarrheal effects promoted by the administration of DIZE to activate the ACE II/Ang-(1-7)/MasR axis in induced diarrhea mice models.	diminazene aceturate	96-100	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	117-120
33684388-4	2021	In this study, we aimed to evaluate the antidiarrheal effects promoted by the administration of DIZE to activate the ACE II/Ang-(1-7)/MasR axis in induced diarrhea mice models.	diminazene aceturate	96-100	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	124-132
33684388-4	2021	In this study, we aimed to evaluate the antidiarrheal effects promoted by the administration of DIZE to activate the ACE II/Ang-(1-7)/MasR axis in induced diarrhea mice models.	diminazene aceturate	96-100	MAS1 oncogene	Mus musculus	134-138
33657582-4	2021	We also investigated the effects of Ang-(1-7) and the ACE-2 activator diminazene aceturate (DIZE) on aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) gene expression, in the absence or presence of the AT1R antagonist irbesartan, or of the MasR antagonist A779.	diminazene aceturate	92-96	cytochrome P450 family 11 subfamily B member 2	Homo sapiens	123-130
32701063-0	2020	ACE2 activator diminazene aceturate ameliorates Alzheimer"s disease-like neuropathology and rescues cognitive impairment in SAMP8 mice.	diminazene aceturate	15-35	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	0-4
33206153-4	2020	Previous studies reported the beneficial effects of oral diminazene aceturate (DIZE) administration, an ACE2 activator, in renal diseases models.	diminazene aceturate	79-83	angiotensin I converting enzyme 2	Rattus norvegicus	104-108
33206153-6	2020	Our findings showed that treatment with DIZE improved renal function and tissue damage by increasing Ang-(1-7) and ACE2 activity, and reducing TNF-alpha.	diminazene aceturate	40-44	angiogenin	Rattus norvegicus	101-109
33206153-6	2020	Our findings showed that treatment with DIZE improved renal function and tissue damage by increasing Ang-(1-7) and ACE2 activity, and reducing TNF-alpha.	diminazene aceturate	40-44	angiotensin I converting enzyme 2	Rattus norvegicus	115-119
33206153-6	2020	Our findings showed that treatment with DIZE improved renal function and tissue damage by increasing Ang-(1-7) and ACE2 activity, and reducing TNF-alpha.	diminazene aceturate	40-44	tumor necrosis factor	Rattus norvegicus	143-152
32800589-4	2020	Considering that angiotensin-converting enzyme 2 (ACE2) is the principal enzyme for the production of Ang-(1-7), here we evaluate the cardiovascular reactivity to acute stress after administration of the ACE2 activator, diminazene aceturate (DIZE) into the BLA.	diminazene aceturate	242-246	angiotensin converting enzyme 2	Homo sapiens	50-54
32800589-6	2020	Administration of DIZE into the BLA (200 pmol/100 nL) attenuated the tachycardia to stress (DeltaHR, bpm: vehicle = 103 +- 17 vs DIZE = 49 +- 7 p = 0.018); this effect was inhibited by Ang-(1-7) antagonist, A-779 (DeltaHR, bpm: DIZE = 49 +- 7 vs A-779 + DIZE = 100 +- 15 p = 0.04).	diminazene aceturate	18-22	angiopoietin 1	Homo sapiens	185-193
32800589-8	2020	NG108 cells treated with DIZE demonstrated decreased expression of l subunit NMDAR-NR1 (NR1 expression (a.u): control = 0.534 +- 0.0593 vs. DIZE = 0.254 +- 0.0260) of NMDAR and increases of Mas receptors expression.	diminazene aceturate	25-29	glutamate ionotropic receptor NMDA type subunit 1	Homo sapiens	83-86
32800589-8	2020	NG108 cells treated with DIZE demonstrated decreased expression of l subunit NMDAR-NR1 (NR1 expression (a.u): control = 0.534 +- 0.0593 vs. DIZE = 0.254 +- 0.0260) of NMDAR and increases of Mas receptors expression.	diminazene aceturate	25-29	glutamate ionotropic receptor NMDA type subunit 1	Homo sapiens	88-91
33029102-5	2020	In this study, we investigated the effects of the ACE2 activator diminazene aceturate (DIZE) on the development of PH secondary to left ventricular dysfunction.	diminazene aceturate	65-85	angiotensin I converting enzyme 2	Rattus norvegicus	50-54
33029102-5	2020	In this study, we investigated the effects of the ACE2 activator diminazene aceturate (DIZE) on the development of PH secondary to left ventricular dysfunction.	diminazene aceturate	87-91	angiotensin I converting enzyme 2	Rattus norvegicus	50-54
33029102-10	2020	DIZE has therapeutic potential for preventing the development of PH secondary to left ventricular dysfunction through ACEII activation and the positive feedback of ANG-(1-7) on the MAS receptor.	diminazene aceturate	0-4	angiogenin	Rattus norvegicus	164-172
32652140-2	2020	Given that diminazene aceturate (DMZ) shares trypanocidal, angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) stimulatory effects, we investigated the impact of DMZ on cardiomyocytes infection in vitro, renin-angiotensin system, Chagas cardiomyopathy and skeletal myositis in vivo.	diminazene aceturate	11-31	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	92-96
32652140-2	2020	Given that diminazene aceturate (DMZ) shares trypanocidal, angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) stimulatory effects, we investigated the impact of DMZ on cardiomyocytes infection in vitro, renin-angiotensin system, Chagas cardiomyopathy and skeletal myositis in vivo.	diminazene aceturate	33-36	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	92-96
32652140-6	2020	DMZ increased ACE2 activity and angiotensin-(1-7) plasma levels but exerted no interference on angiotensin-converting enzyme (ACE) activity, ACE, ACE2 and angiotensin II levels in uninfected and infected mice.	diminazene aceturate	0-3	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	14-18
32652140-6	2020	DMZ increased ACE2 activity and angiotensin-(1-7) plasma levels but exerted no interference on angiotensin-converting enzyme (ACE) activity, ACE, ACE2 and angiotensin II levels in uninfected and infected mice.	diminazene aceturate	0-3	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	14-17
33206153-0	2020	ACE2 activator diminazene aceturate exerts renoprotective effects in gentamicin-induced acute renal injury in rats.	diminazene aceturate	15-35	angiotensin I converting enzyme 2	Rattus norvegicus	0-4
33206153-4	2020	Previous studies reported the beneficial effects of oral diminazene aceturate (DIZE) administration, an ACE2 activator, in renal diseases models.	diminazene aceturate	57-77	angiotensin I converting enzyme 2	Rattus norvegicus	104-108
32603499-1	2020	Diminazene aceturate (DIZE) has been described as an angiotensin-converting enzyme 2 (ACE2) activator.	diminazene aceturate	0-20	angiotensin I converting enzyme 2	Rattus norvegicus	53-84
32603499-1	2020	Diminazene aceturate (DIZE) has been described as an angiotensin-converting enzyme 2 (ACE2) activator.	diminazene aceturate	0-20	angiotensin I converting enzyme 2	Rattus norvegicus	86-90
32603499-1	2020	Diminazene aceturate (DIZE) has been described as an angiotensin-converting enzyme 2 (ACE2) activator.	diminazene aceturate	22-26	angiotensin I converting enzyme 2	Rattus norvegicus	53-84
32603499-1	2020	Diminazene aceturate (DIZE) has been described as an angiotensin-converting enzyme 2 (ACE2) activator.	diminazene aceturate	22-26	angiotensin I converting enzyme 2	Rattus norvegicus	86-90
32800589-4	2020	Considering that angiotensin-converting enzyme 2 (ACE2) is the principal enzyme for the production of Ang-(1-7), here we evaluate the cardiovascular reactivity to acute stress after administration of the ACE2 activator, diminazene aceturate (DIZE) into the BLA.	diminazene aceturate	220-240	angiotensin converting enzyme 2	Homo sapiens	17-48
32800589-4	2020	Considering that angiotensin-converting enzyme 2 (ACE2) is the principal enzyme for the production of Ang-(1-7), here we evaluate the cardiovascular reactivity to acute stress after administration of the ACE2 activator, diminazene aceturate (DIZE) into the BLA.	diminazene aceturate	220-240	angiotensin converting enzyme 2	Homo sapiens	50-54
32800589-4	2020	Considering that angiotensin-converting enzyme 2 (ACE2) is the principal enzyme for the production of Ang-(1-7), here we evaluate the cardiovascular reactivity to acute stress after administration of the ACE2 activator, diminazene aceturate (DIZE) into the BLA.	diminazene aceturate	242-246	angiotensin converting enzyme 2	Homo sapiens	17-48
32716174-6	2020	Finally, we apply PNO-CC3 to the calculation of the first excited state of berenil at a S1 minimum geometry, which is shown to be close to a conical intersection.	diminazene aceturate	75-82	C-C motif chemokine ligand 14	Homo sapiens	22-25
32380079-0	2020	Diminazene aceturate extenuate the renal deleterious consequences of angiotensin-II induced by gamma-irradiation through boosting ACE2 signaling cascade.	diminazene aceturate	0-20	angiotensinogen	Rattus norvegicus	69-83
32380079-0	2020	Diminazene aceturate extenuate the renal deleterious consequences of angiotensin-II induced by gamma-irradiation through boosting ACE2 signaling cascade.	diminazene aceturate	0-20	angiotensin I converting enzyme 2	Rattus norvegicus	130-134
32380079-1	2020	AIM: This work aims to explore the role of diminazene aceturate (DIZE) in the enhancement of angiotensin-converting enzyme-2 (ACE2) to prevent the inflammatory and fibrotic response induced by gamma-irradiation through activating the protective axis ACE2/angiotensin (1-7)/Mas receptor (ACE2/Ang(1-7)/Mas).	diminazene aceturate	43-63	angiotensin I converting enzyme 2	Rattus norvegicus	93-124
32380079-1	2020	AIM: This work aims to explore the role of diminazene aceturate (DIZE) in the enhancement of angiotensin-converting enzyme-2 (ACE2) to prevent the inflammatory and fibrotic response induced by gamma-irradiation through activating the protective axis ACE2/angiotensin (1-7)/Mas receptor (ACE2/Ang(1-7)/Mas).	diminazene aceturate	43-63	angiotensin I converting enzyme 2	Rattus norvegicus	126-130
32380079-1	2020	AIM: This work aims to explore the role of diminazene aceturate (DIZE) in the enhancement of angiotensin-converting enzyme-2 (ACE2) to prevent the inflammatory and fibrotic response induced by gamma-irradiation through activating the protective axis ACE2/angiotensin (1-7)/Mas receptor (ACE2/Ang(1-7)/Mas).	diminazene aceturate	43-63	angiotensin I converting enzyme 2	Rattus norvegicus	250-254
32380079-1	2020	AIM: This work aims to explore the role of diminazene aceturate (DIZE) in the enhancement of angiotensin-converting enzyme-2 (ACE2) to prevent the inflammatory and fibrotic response induced by gamma-irradiation through activating the protective axis ACE2/angiotensin (1-7)/Mas receptor (ACE2/Ang(1-7)/Mas).	diminazene aceturate	43-63	angiotensin I converting enzyme 2	Rattus norvegicus	250-254
32380079-1	2020	AIM: This work aims to explore the role of diminazene aceturate (DIZE) in the enhancement of angiotensin-converting enzyme-2 (ACE2) to prevent the inflammatory and fibrotic response induced by gamma-irradiation through activating the protective axis ACE2/angiotensin (1-7)/Mas receptor (ACE2/Ang(1-7)/Mas).	diminazene aceturate	43-63	angiogenin	Rattus norvegicus	292-299
32380079-1	2020	AIM: This work aims to explore the role of diminazene aceturate (DIZE) in the enhancement of angiotensin-converting enzyme-2 (ACE2) to prevent the inflammatory and fibrotic response induced by gamma-irradiation through activating the protective axis ACE2/angiotensin (1-7)/Mas receptor (ACE2/Ang(1-7)/Mas).	diminazene aceturate	65-69	angiotensin I converting enzyme 2	Rattus norvegicus	93-124
32380079-1	2020	AIM: This work aims to explore the role of diminazene aceturate (DIZE) in the enhancement of angiotensin-converting enzyme-2 (ACE2) to prevent the inflammatory and fibrotic response induced by gamma-irradiation through activating the protective axis ACE2/angiotensin (1-7)/Mas receptor (ACE2/Ang(1-7)/Mas).	diminazene aceturate	65-69	angiotensin I converting enzyme 2	Rattus norvegicus	126-130
32380079-1	2020	AIM: This work aims to explore the role of diminazene aceturate (DIZE) in the enhancement of angiotensin-converting enzyme-2 (ACE2) to prevent the inflammatory and fibrotic response induced by gamma-irradiation through activating the protective axis ACE2/angiotensin (1-7)/Mas receptor (ACE2/Ang(1-7)/Mas).	diminazene aceturate	65-69	angiotensin I converting enzyme 2	Rattus norvegicus	250-254
32380079-1	2020	AIM: This work aims to explore the role of diminazene aceturate (DIZE) in the enhancement of angiotensin-converting enzyme-2 (ACE2) to prevent the inflammatory and fibrotic response induced by gamma-irradiation through activating the protective axis ACE2/angiotensin (1-7)/Mas receptor (ACE2/Ang(1-7)/Mas).	diminazene aceturate	65-69	angiotensin I converting enzyme 2	Rattus norvegicus	250-254
32380079-1	2020	AIM: This work aims to explore the role of diminazene aceturate (DIZE) in the enhancement of angiotensin-converting enzyme-2 (ACE2) to prevent the inflammatory and fibrotic response induced by gamma-irradiation through activating the protective axis ACE2/angiotensin (1-7)/Mas receptor (ACE2/Ang(1-7)/Mas).	diminazene aceturate	65-69	angiogenin	Rattus norvegicus	292-299
32701063-4	2020	Since Ang-(1-7) is generated by its metabolic enzyme ACE2, we then tested the efficacy of an ACE2 activator diminazene aceturate (DIZE) on AD-like neuropathology and cognitive impairment in senescence-accelerated mouse prone substrain 8 (SAMP8) mice, an animal model of sporadic AD.	diminazene aceturate	108-128	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	6-14
32701063-4	2020	Since Ang-(1-7) is generated by its metabolic enzyme ACE2, we then tested the efficacy of an ACE2 activator diminazene aceturate (DIZE) on AD-like neuropathology and cognitive impairment in senescence-accelerated mouse prone substrain 8 (SAMP8) mice, an animal model of sporadic AD.	diminazene aceturate	108-128	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	93-97
32701063-4	2020	Since Ang-(1-7) is generated by its metabolic enzyme ACE2, we then tested the efficacy of an ACE2 activator diminazene aceturate (DIZE) on AD-like neuropathology and cognitive impairment in senescence-accelerated mouse prone substrain 8 (SAMP8) mice, an animal model of sporadic AD.	diminazene aceturate	130-134	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	93-97
32701063-11	2020	These beneficial effects of DIZE may be achieved by activating brain ACE2/Ang-(1-7)/MAS1 axis.	diminazene aceturate	28-32	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	69-73
32701063-11	2020	These beneficial effects of DIZE may be achieved by activating brain ACE2/Ang-(1-7)/MAS1 axis.	diminazene aceturate	28-32	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	74-82
32701063-11	2020	These beneficial effects of DIZE may be achieved by activating brain ACE2/Ang-(1-7)/MAS1 axis.	diminazene aceturate	28-32	MAS1 oncogene	Mus musculus	84-88